Levosimendan with other inotropes or vasopressors: Should you combine them? - 10/12/20
Doi : 10.1016/j.ajem.2020.03.059
Gonçalo J.L. Cunha a, ⁎, 1 
, Bruno M.L. Rocha a, 1, Rita V. Gomes b, 1, Mário Ferraz c, Lúcia Fernandes d, Rui Morais d, Luís Campos d, e, Inês Araújo d, Cândida Fonseca d, e
, Bruno M.L. Rocha a, 1, Rita V. Gomes b, 1, Mário Ferraz c, Lúcia Fernandes d, Rui Morais d, Luís Campos d, e, Inês Araújo d, Cândida Fonseca d, e a Serviço de Cardiologia, Hospital de Santa Cruz, Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal
b Serviço de Cardiologia, Hospital Vila Franca de Xira, Lisbon, Portugal
c Serviço de Medicina, Centro Hospitalar Universitário Lisboa Central, Lisboa, Portugal
d Clínica de Insuficiência Cardíaca, Hospital de São Francisco Xavier, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal
e NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Portugal
⁎Corresponding author.
Highlights |
• | In our AHF unit, levosimendan was often combined with other inotropes/vasopressors. |
• | Such combination (LVc) was well-tolerated compared to isolated levosimendan (LVi). |
• | No differences in adverse events nor intra-hospital death were found between groups. |
• | The safety and effectiveness of combination treatment is worth being further assessed. |
© 2020
Elsevier Inc. Tous droits réservés.
Vol 38 - N° 12
P. 2723-2726 - décembre 2020 Retour au numéro
Article précédent
- Intravenous thiamine for septic shock: A meta-analysis of randomized controlled trials
- Xiangfeng Qian, Zhe Zhang, Feng Li, Longchuan Wu
- Patients accept screening for mental health and substance use disorders while ED clinicians support only if able to refer
- Sacha A. McBain, Eva Woodward, Brooke E. Palmer, Sara J. Landes, Michael P. Wilson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?